Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 13, 2013 - Issue 11
Submit an article Journal homepage
574
Views
35
CrossRef citations to date
0
Altmetric
Drug Profiles

Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression

Tanja VeselinovićDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany and;Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Pauwelsstr. 30 52074 Aachen, Germany
,
Michael PaulzenDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany and;Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Pauwelsstr. 30 52074 Aachen, Germany
&
Gerhard GründerDepartment of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen University, Aachen, Germany and;Jülich Aachen Research Alliance JARA, Translational Brain Medicine, Pauwelsstr. 30 52074 Aachen, GermanyCorrespondence[email protected]
Pages 1141-1159 | Published online: 09 Jan 2014

References

  • Bhugra D. The global prevalence of schizophrenia. PLoS Med. 2(5), e141, quiz e175 (2005).
  • Reichenberg A, Weiser M, Caspi A et al. Premorbid intellectual functioning and risk of schizophrenia and spectrum disorders. J. Clin. Exp. Neuropsychol. 28(2), 193–207 (2006).
  • Heinrichs RW. The primacy of cognition in schizophrenia. Am. Psychol. 60 (3), 229–242 (2005).
  • Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry. 153 (3), 321–330 (1996).
  • Delay J, Deniker P, Harl JM. [Therapeutic use in psychiatry of phenothiazine of central elective action (4560 RP)]. Ann. Med. Psychol. (Paris) 110(2 1), 112–117 (1952).
  • Brodie BB, Olin JS, Kuntzman RG, Shore PA. Possible interrelationship between release of brain norepinephrine and serotonin by reserpine. Science 125(3261), 1293–1294 (1957).
  • Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Copenh.) 20, 140–144 (1963).
  • Keefe RS, Bilder RM, Davis SM et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch. Gen. Psychiatry 64 (6), 633–647 (2007).
  • Hippius H. The founding of the CINP and the discovery of clozapine. In: The Psychopharmacologists. Healy D ( Ed.), Chapman & Hall, NY, USA, 185–213 (1996).
  • Shen WW. A history of antipsychotic drug development. Compr. Psychiatry 40(6), 407–414 (1999).
  • Chiodo LA, Bunney BS. Possible mechanisms by which repeated administration differentially affects the activity of two subpopulations of midbrain dopamine neurons. J. Neurosci. 5, 2525–2544 (1985).
  • Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251(1), 238–246 (1989).
  • Kapur S, Seeman P. Does Fast Dissociation From the Dopamine D2 Receptor Explain the Action of Atypical Antipsychotics? A New Hypothesis. Am. J. Psychiatry 158, 360–369 (2001).
  • Kinon BJ, Lieberman JA. Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.) 124(1–2), 2–34 (1996).
  • Gründer G. Antipsychotika. In: Handbuch der Psycopharmakotherapie. Gründer G, Benkert O ( Ed.), Springer Medizin, Heidelberg, Germany, 659–692 (2011).
  • Urban JD, Clarke WP, von Zastrow M et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1–13 (2007).
  • Burris KD, Molski TF, Xu C et al. Aripirazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302, 381–389 (2002).
  • Shapiro DA, Renock S, Arrington EB et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400–1411 (2003).
  • Gründer G, Hippius H, Carlsson A. The ‘atypicality’ of antipsychotics: a concept re-examined and re-defined. Nat. Rev. Drug Discov. 8(3), 197–202 (2009).
  • Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane JM, Correll CU. Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: a systematic review and meta-analysis. Int. J. Neuropsychopharmacol. 3, 1–14 (2012).
  • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry. 60, 553–564 (2003).
  • Gray JA, Roth BL. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull. 33 (5), 1100–1119 (2007).
  • Miyamoto S, Jarskog LF, Fleischhacker WW. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry 26(2), 158–65 (2013).
  • Joyce JN, Millan MJ. Dopamine D3 receptor antagonists as therapeutic agents. Drug Discov. Today. 10 (13), 917–925 (2005).
  • Laszy J, Laszlovszky I, Gyertyán I. Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats. Psychopharmacology (Berl.) 179 (3), 567–575 (2005).
  • Gründer G. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression. Curr. Opin. Investig. Drugs 11(7), 823–832 (2010).
  • Ágai-Csongor E, Nógrádi K, Galambos J et al. Novel sulfonamides having dual dopamine D2 and D3 receptor affinity show in vivo antipsychotic efficacy with beneficial cognitive and EPS profile. Bioorg. Med. Chem. Lett. 17 (19) 5340–5344 (2007).
  • Gyertyán I, Sághy K, Laszy J et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15. Naunyn Schmiedeberg’s Arch. Pharmacol. 378(5), 529–39 (2008).
  • Kiss B, Laszlovszky I, Horváth A et al. Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15. Naunyn Schmiedeberg’s Arch. Pharmacol. 378(5), 515–528 (2008).
  • Ágai-Csongor É, Domány G, Nógrádi K et al. Discovery of cariprazine (RGH-188): A novel antipsychotic acting on dopamine D 3/D2 receptors. Bioorg. Med. Chem. Lett. 22 (10), 3437–3440 (2012).
  • Kiss B, Schmidt E, Horváth A et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333(1), 328–340 (2010).
  • Gyertyán I, Kiss B, Sághy K et al. Pharmacological profile of RGH-188, a novel dopamine D3/D2 receptor antagonist/partial agonist atypical antipsychotic. Eur. Neuropsychopharmacol. 16( Suppl. 4), 432 (2006).
  • Kiss B, Laszlovszky I, Horváth A et al. RGH-188, an atypical antipsychotic with dopamine d-3/d-2 antagonist/partial agonist properties: in vitro characterisation. Int. J. Neuropsychopharmacol. 9, 221–222 (2006).
  • Seneca N, Finnema SJ, Laszlovszky I et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl.) 218(3), 579–587 (2011).
  • Laszlovszky I, Németh G, Mészáros GP et al. Positron emission tomography (PET) study with RGH-188 in healthy volunteers. Biol. Psychiatry 63(7) (2008).
  • Laszlovszky I, Németh G, Mészáros GP et al. Dopamine D2/D3 receptor occupancy of RGH-188, a D3/D2 antagonist/partial agonist antipsychotic, in healthy volunteers. Eur. Neuropsychopharmacol. 17( Suppl. 4), S454 (2007).
  • Potkin S, Keator D, Mukherjee J et al. Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur. Neuropsychopharmacol. 19, S316 (2009).
  • Keator DB, Mukherjee J, Preda A et al. Dopamine D2 and D3 receptor occupancy of cariprazine in schizophrenic patients. Schizophr. Bull. 35, 154 (2009).
  • Kiss B, Gyertyán I, Ágai-Csongor E, Domány G, Tihanyi K, Szombathelyi Z. RGH-188, an atypical antipsychotic with dopamine D-3/D-2 antagonist/partial agonist properties: Neurochemical characterisation Int J Neuropsychopharmacol. 9 ( Suppl. 1), 222 (2006).
  • Adham-Parangi N, Kiss B, Gyertyán I, Gupta S, Szombathelyi Z, Ashby C. RGH-188, potential antipsychotic with D3/D2 antagonist/partial agonist properties, exhibits an atypical antipsychotic profile in rats with respect to effect oil spontaneously active dopamine neurons. Int. J. Neuropsychopharmacology 11 ( Suppl. 1), 263 (2008).
  • Tarazi F, Choi YK, Adham N, Kiss B, Gyertyán I. Effects of Chronic Cariprazine Administration on Serotonin and Glutamate Receptor Subtypes. Presented at: 51st Annual Meeting of ACNP, Hollywood, Florida, USA, 2–6 December (2012).
  • Gyertyán I, Kiss B, Sághy K et al. RGH-188, a D3/D2 dopamine receptor partial agonist antipsychotic candidate with excellent brain availability and low EPS liability. Biol. Psychiatry 61(8), 76 (2007).
  • Mészáros GP, Bolf ET, Gémesi L, Kapás M, Tihanyi K, Szombathelyi Z. Pharmacokinetics of RGH-188, a novel dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in rats and dogs. Eur. Neuropsychopharmacol. 18 ( Suppl. 4), 456–457 (2008).
  • Kirschner N, Gémesi LI, Vastag M et al. In vitro metabolism of RGH-188. Drug Metab Rev. 40, 128–129 (2008).
  • Kapás M, Mészáros GP, Yu B et al. Comparison of the pharmacokinetic behaviour of RGH-188 in schizophrenic patients and healthy volunteers. Eur. Neuropsychopharmacol. 18( Suppl. 4), 433 (2008).
  • Ereshefsky L, Gage A, Yu B et al. Phase I study of RGH-188 in schizophrenic patients I. Int. J. Neuropsychopharmacol. 11( Suppl. 1), 140 (2008).
  • Mészáros GP, Kapás M, Borsos M et al. Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects Eur. Neuropsychopharmacol. 17( Suppl. 4), S451–S452 (2007).
  • Laszlovszky I, Kiss B, Gyertyán I et al. RGH-188, a D3/D2 dopamine receptor antagonist/partial agonist atypical antipsychotic candidate. Eur. Psychiatry 23( Suppl. 2) S163 (2008).
  • Bose A, Li D, Migliore R, Werner P, Németh G, Laszlovszky I. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. Abstracts of the 19th European Congress of Psychiatry. Eur. Psychiatry 26( Suppl.1), 1354 (2011).
  • Cutler AJ, Bose A, Durgam S et al. Safety and tolerability of cariprazine in the long–term treatment of schizophrenia: results from a 48–week extension study. Presented at the American Psychiatric Association (APA) 165th Annual Meeting, Philadelphia, USA, 5–9 May 2012.
  • Zukin SR, Kane J, Cutler AJ et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: a phase III, international, randomized, double-blind, placebo-controlled trial. Presented at: 51st Annual Meeting of ACNP, Hollywood, Florida, USA, 2–6 December 2012.
  • Knesevich MA, Papadakis K, Bose A, Wang Q, Korotzer A, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Bipolar. Disord. 11( Suppl. 1), 54 (2009).
  • Knesevich M, Papadakis K, Bose A, Andor G, Laszlovszky I. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: A phase II trial. Eur. Neuropsychopharmacol. 19, 469–470 (2009).
  • Bose A, Wang Q, Diaz E et al. Cariprazine in the treatment of acute mania in bipolar disorder: a double–blind, placebo–controlled, phase III trial. Presentet at: American Psychiatric Association’s (APA) Annual Meeting, Philadelphia, Pennsylvania, USA, 5–9 May 2012.
  • Davis JM, Chen N, Glick ID A meta-analysis of the efficacy of second-generation an-tipsychotics. Arch. Gen. Psychiatry 60 (6), 553–564 (2003).
  • Naber D, Lambert M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs 23(8), 649–659 (2009).
  • Miyamoto S, Miyake N, Jarskog LF et al. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol. Psychiatry 17, 1206–1227 (2012).
  • Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. Suppl. (438), 7–14 (2009).
  • Gyertyán I, Kiss B, Sághy K et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem. Int. 59, 925–935 (2011).
  • Zimnisky R, Chang G, Gyertyán I, Kiss B, Adham N, Schmauss C. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse. Psychopharmacology (Berl.) 226(1), 91–100 (2013).
  • Gross G, Drescher K. The role of dopamine D(3) receptors in antipsychotic activity and cognitive functions. Handb. Exp. Pharmacol. 213, 167–210 (2012).
  • Sokoloff P, Leriche L, Diaz J, Louvel J, Pumain R. Direct and indirect interactions of the dopamine D3 receptor Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia. Naunyn-Schmiedeberg’s Arch. Pharmacol. 386(2), 107–124 (2013).
  • Lacroix LP, Ceolin L, Zocchi A et al. Selective dopamine D3 receptor antagonists enhance cortical acetylcholine levels measured with high-performance liquid chromatography/tandem mass spectrometry without anti-cholinesterases. J. Neurosci. Methods 157(1), 25–31 (2006).
  • Bervoets C, Morrens M, Vansteelandt K et al. Effect of aripiprazole on verbal memory and fluency in schizophrenic patients: results from the ESCAPE study. CNS Drugs 26(11), 975–982 (2012).
  • Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J. Psychopharmacol. 26(6), 806–812 (2012).
  • Tohen M, Sanger TM, McElroy SL et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am. J. Psychiatry 156(5), 702–709 (1999).
  • Duman RS, Duric V, Banasr M, Adham N, Kiss B, Gyertyán I. Cariprazine exhibits dopamine D3 receptor-dependent antidepressant-like activity in the chronic un-predictable stress model of anhedonia. Presented at: 51st Annual Meeting of ACNP, Hollywood, Florida, USA, 2–6 December 2012.
  • Román V, Gyertyán I, Sághy K, Kiss B, Szombathelyi Z. Cariprazine (RGH-188), a D(3)-preferring dopamine D (3)/D (2) receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. Psychopharmacology (Berl.226(2), 285–293 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.